For example, recently we reported that FEA associated with statin treatment in PAD patients was able to reduce in circulating polymorphonuclear leukocytes Angiotensin II (Ang II) type 1 receptor expression (a receptor pathway extensively involved in the proinflammatory and proatherogenic effects of Ang II) [21]. Here, AGT is linked to peripheral arterial disease.